The present invention relates to a current mirror circuit capable of a broad range of uses requiring controlled delivery of electrical current and finding particular utility in functional electrical stimulation (FES) applications.
Typically in FES applications, current stimulators are used for providing programmable current pulses directed through an electrode to stimulate targeted neuromuscular tissue. The amplitude and duration of the current pulses delivered through the electrode are usually programmed through a digital to analog converter (DAC). The current output from the DAC is normally amplified to the desired output current amplitude at the current stimulator. The current amplification is typically accomplished using a current mirror circuit and in particular for MOSFET devices, the current gain is achieved by controlling the device semiconductor die width (W) to length (L) ratio (W/L) of the input side and output side transistors of a current mirror. For example, in the prior art current mirror circuit of
Errors regarding the amplitudes of the current delivered arise mainly due to the finite output impedance of the stimulator and any mismatch errors between the input side transistor M1 and the output side transistor M2. One technique to compensate for the effects of the output impedance of the stimulator is to configure the circuit of
In advanced applications it is contemplated that stimulator output current is to be individually and independently programmed through a plurality of electrodes rather than through just a single electrode. For a candidate circuit as is shown in
As shown in
Furthermore, a design may be helpful in some instances to ensure fast turn on time under different output current levels including small output current delivery conditions especially with a multiplicity of programmable stimulating electrodes that are capable of outputting large current levels. However, in many stimulator designs, the turn on times for delivering small output current levels are usually very long. This is mainly due to the fact that only small currents are available to flow through the transistors for small output current levels to charge the parasitic capacitances of the transistors, especially the gate-to-source capacitances. The turn on times are even longer, especially for high voltage stimulators that can be programmed to have large current outputs. For these high voltage stimulators, very large high voltage transistors are required for the required large output current levels due to the relatively low gain of these transistors. Also, due to the relatively high threshold voltages associated with these high voltage transistors, it will take longer time to have the small current outputs charging up the gate-to-source voltages to higher than the threshold voltages in order to turn on these high voltage transistors.
One non-limiting embodiment of the present invention includes pairs of transistors, preferably MOSFET transistors, each pair being connected in a current mirror configuration and coupled to a supply transistor in a cascode arrangement. Each pair of transistors has an input side transistor and an output side transistor, the output side transistor of each pair being electrically coupled to a respective and corresponding tissue stimulating electrode. The output side transistors therefore implement a circuit for providing multiple current stimulator capability. The present invention also includes an operational or differential amplifier having one input coupled to a reference voltage and another input coupled to the output side transistors and an output which drives the supply transistor. In steady state, the operational amplifier maintains the voltage at the output side transistor equal to the reference voltage.
In some instances, a current source supplies constant current through a first resistor to establish the reference voltage and a voltage source supplies all the stimulation current through a second resistor to establish the voltage at the output side transistor. A current gain K which represents the factor that multiplies the value of the constant current to provide the total stimulation current is equal to the ratio of the values of the first resistor and the second resistor. In such a manner, the present invention avoids dependency on the MOSFET transistor's width and length values defined in a corresponding semiconductor chip but relies on the more dependable resistor values to achieve the required current gain.
In some instances, advantageously, at circuit turn on, the output of the operational amplifier is very large due to the difference in amplifier input voltages and thus the supply transistor which is driven by the operational amplifier provides large initial currents to discharge the capacitances associated with the output side transistors which results in a major improvement (reduction) in stimulator turn on time almost independent of the number of stimulator outputs.
One embodiment of the present disclosure relates to a peripherally-implantable neurostimulation system. The peripherally-implantable neurostimulation system can include a pulse generator including a reference current generator that generates a reference current, and a multiple output current stimulator circuit. In some embodiments, the multiple output current stimulator circuit can include a current source that can be, for example, connected to the reference current generator. The multiple output current stimulator circuit can include a first resistor coupled to the current source to provide a reference voltage, and at least one output side transistor having a current output terminal for providing an output current. In some embodiments, the multiple output current stimulator circuit can include a second resistor coupled between a voltage source and the at least one output side transistor to thereby provide a common sensing voltage, and a differential amplifier. In some embodiments, the differential amplifier can include a first input coupled to the reference voltage, a second input coupled to the common sensing voltage, and an output arranged to drive the at least one output side transistor as a function of the difference between the reference voltage and the common sensing voltage.
In some embodiments, the peripherally-implantable neurostimulation system can include a lead connected to the pulse generator. This lead can include a plurality of conductive electrodes and plurality of non-conductive regions. In some embodiments of the peripherally-implantable neurostimulation system, the pulse generator can include a plurality of electrical pulse programs that can, for example, affect the frequency and strength of electrical pulses generated by the pulse generator.
In some embodiments, the peripherally-implantable neurostimulation system can include a controller that can communicate with the pulse generator to create one of the plurality of electrical pulse programs and/or a controller that can communicate with the pulse generator to select one of the plurality of electrical pulse programs. In some embodiments, the peripherally-implantable neurostimulation system can include a first switch located between the output of the differential amplifier and the output side transistor. This first switch can be closed according to one of the plurality of electrical pulse programs.
One embodiment of the present disclosure relates to a peripherally-implantable neurostimulation system. The system includes a pulse generator that can generate one or several electrical pulses. The pulse generator can include a current generator that can generate a reference current, and a stimulator that includes a stimulator circuit. In some embodiments, the stimulator circuit amplifies the reference current according to a ratio of resistances of a first resistor and a second resistor. The system can include one or more leads connected to the pulse generator. In some embodiments, the one or more leads can include one or more electrodes and the one or more leads can conduct the one or several electrical pulses from the pulse generator to the one or more electrodes.
In some embodiments of the peripherally-implantable neurostimulation system the stimulator circuit can include a differential amplifier having a first input and a second input. In some embodiments, the first resistor can be coupled to the first input and the second resistor can be coupled to the second input.
In some embodiments the peripherally-implantable neurostimulation system includes a plurality of outputs in electrical connection with the second resistor, and in some embodiments of the system, a stimulator output current flowing through the second resistor is equal to the sum of the current flowing through the outputs. In some embodiments of the peripherally-implantable neurostimulation system, one or both of the first resistor and the second resistor can be a plurality of resistors. In some embodiments of the peripherally-implantable neurostimulation system the plurality of resistors of the first resistor can be arranged in series, and/or in some embodiments, the plurality of resistors of the second resistor can be arranged in parallel.
One embodiment of the present disclosure relates to a peripherally-implantable neurostimulation system. The system includes a pulse generator that can generate one or several electrical pulses. The pulse generator can include a current generator that can generate a reference current, and a stimulator including a stimulator circuit. In some embodiments, the stimulator circuit can include a supply transistor having an output connected to one or several gates of one or several output transistors. The system can include one or more leads connected to the pulse generator, which one or more leads can include one or more electrodes. In some embodiments, the one or more leads can conduct the one or several electrical pulses from the pulse generator to the one or more electrodes.
In some embodiments of the peripherally-implantable neurostimulation system, the drain of the supply transistor can be connected to one or several gates of one or several output transistors. In some embodiments, the peripherally-implantable neurostimulation system can include a differential amplifier. In some embodiments, the output of the differential amplifier can be arranged to drive the supply transistor.
One embodiment of the present disclosure relates to a method of treating neuropathic pain. The method can include implanting a pulse generator in a peripheral portion of a body, which pulse generator can generate one or several electrical pulses. In some embodiments, the pulse generator can include a stimulator circuit that can amplify the reference current according to a ratio of resistances of a first resistor and a second resistor. In some embodiments, the method can include implanting a lead within the peripheral portion of the body, which lead can include one or more electrodes, positioning the one or more electrodes of the lead proximate to a peripheral nerve, and connecting the lead to the pulse generator.
In some embodiments, the method of treating neuropathic pain can further include generating an electrical pulse with the pulse generator; and conducting the electrical pulse to the peripheral nerve with the lead.
One embodiment of the present disclosure relates to a method of treating neuropathic pain. The method can include implanting a pulse generator in a peripheral portion of a body, which pulse generator can generate one or several electrical pulses. In some embodiments, the pulse generator can include a stimulator circuit that can include a supply transistor having an output connected to one or several gates of one or several output transistors. In some embodiments, the method can include implanting a lead within the peripheral portion of the body, which lead can include one or more electrodes, positioning the one or more electrodes of the lead proximate to a peripheral nerve, and connecting the lead to the pulse generator.
In some embodiments, the method of treating neuropathic pain can include generating an electrical pulse with the pulse generator, and conducting the electrical pulse to the peripheral nerve with the lead.
One embodiment of the present disclosure relates to a peripherally-implantable neurostimulation system. The system includes a pulse generator that can generate one or several electrical pulses. The pulse generator can include a current generator that can generate a reference current, and a stimulator that can include a stimulator circuit. In some embodiments, the stimulator circuit has a turn on time of less than 5 us for an output current of less than 50 mA. In some embodiments, the system can include one or more leads connected to the pulse generator. In some embodiments, the one or more leads can include one or more electrodes, which one or more leads can conduct the one or several electrical pulses from the pulse generator to the one or more electrodes.
In some embodiments of the peripherally-implantable neurostimulation system, the turn on time is less than 2 us for an output current between 200 uA and 25 mA. In some embodiments of the peripherally-implantable neurostimulation system, the turn on time is between 0.5 and 2 us for an output current between 200 uA and 25 mA. In some embodiments of the peripherally-implantable neurostimulation system, the pulse generator can generate at least one electrical pulse having a pulse width of 50 us.
One embodiment of the present disclosure relates to a neurostimulation system. The neurostimulation system includes an implantable pulse generator. In some embodiments, the implantable pulse generator includes a first resistance, a reference signal generator that can generate a reference signal, the reference signal being at least one of a reference voltage extending across, or a reference current flowing through the first resistance, and a second resistance. In some embodiments, the neurostimulation system can include a plurality of electrode outputs, and a multi-output stimulator that can amplify the reference signal to a total output signal. In some embodiments, the total output signal can be at least one of a total output voltage or a total output current extending across or flowing through the second resistance. In some embodiments, the multi-output stimulator can distribute the total output signal to at least some of the plurality of electrode outputs. In some embodiments, a gain value of the amplification by the multi-output stimulator is based on the first resistance and the second resistance. In some embodiments, the neurostimulation system can include one or more leads that include a plurality of electrodes that can be coupled to the plurality of electrode outputs.
In some embodiments of the neurostimulation system, the gain value of the amplification by the multi-output stimulator is equal to the first resistance divided by the second resistance. In some embodiments of the neurostimulation system, the first resistance can include a plurality of resistors in series, and in some embodiments, the second resistance can include a plurality of resistors in parallel. In some embodiments of the neurostimulation system, the implantable pulse generator is sized for implantation in a peripheral portion of a human body, and in some embodiments, the peripheral portion of the human body can be one of an arm, a leg, a hand, and a foot.
Referring now to
Digital registers 2 also store information regarding stimulation pulse duration, amplitude and profile as well as other operational parameters. Based upon information stored in digital registers 2 and the CLOCK signal, stimulation controller 30 generates the desired stimulation pulse amplitude and triggers digital to analog converter DAC 4 to generate an output. Based upon the DAC 4 output, reference current source generator 6 provides a sink for Isink current (shown as Isink PORT in
With reference to
Advantageously in some instances, in the embodiment depicted in
Circuit 11A further includes at least one transistor. The source of transistor MC(2) is connected to voltage source VS through resistor R2. The source of transistor MC(2) is also connected to the negative input of op amp 16 and provides a sensing voltage to op amp 16. The drain of transistor MC(2), designated as OUT(2), is coupled to a respective electrode (not shown) for delivery of stimulation current to the tissue in contact with such respective electrode.
As further seen, in
Furthermore, at the same time, to ensure suspension of current delivery from output OUT(2), logic circuits 35 cause switch SB(1) to be activated. Stimulation therapy may be wirelessly controlled by an auxiliary device, such as a remote control or smart phone, to control the timing and duration of the activation of switches SA(1) and SB(1) so as to provide the desired current delivery in accordance with a predetermined therapy protocol. Preferably, logic circuits 35 control the states of switches SA(1) and SB(1) in a complementary fashion such that when switch SA(1) is activated, switch SB(1) is de-activated and vice versa.
Overall switching control can be accomplished by utilizing stimulation controller 30, digital registers 2 and logic circuits 35, either singly or in combination depending upon functional considerations.
In some embodiments, voltage VR1 is generated across resistor R1 when the current Isink flows from voltage source VS through resistor R1. In a like manner, voltage VR2 is generated across R2 when the overall stimulator output current IR2 flows through resistor R2 from voltage source VS. The voltage at the positive input of op amp 16 is the voltage sensed at the sources of transistors MC(1) to MC(n) when the corresponding switches SA(1) to SA(n) are activated and may be considered a common sensing voltage. Uniquely, and due to the feedback loop associated with op amp 16, the voltages at the positive and negative inputs of op amp 16 will be equal in steady state, and therefore, voltage VR2 is forced to be equal to VR1. At steady state, the current IR2 is equal to the sum of the output currents being delivered at all of the outputs OUT(2) to OUT(n). Accordingly, since VR2=IR2·R2 and VR1=Isink·R1, IR2 is equal to Isink·R1/R2 and the required overall current gain K defined as IR2/Isink, is therefore equal to R1/R2. Accordingly, setting the required overall current gain K is a matter of selecting the values of R1 and R2.
In some non-limiting applications, resistors may have better matched characteristics than MOSFETs in an integrated circuit as a function of area. For the same part to part matching accuracy, using resistors as described herein uses less area on an integrated circuit than using MOSFETs. An additional benefit in some instances may arise from the manner in which the resistors R1 and R2 may be constructed. For example, resistor R2 may be made from a number (Np) of parallel resistors and R1 may be made from a number (Ns) of series resistors. Accordingly, for a resistor value R, R1=R·Ns and R2=R/Np and the current gain K=R1/R2=Ns·Np. For the case when Ns=Np=N, the current gain K=N2 and with the total number of resistors equal to 2N (Ns+Np=2N), the total number of resistors as a function of current gain therefore is equal to 2·K1/2. For a current gain of 100, the number of resistors is 20, whereas a total of 101 individual transistors are required for M1 and M2 (See
With reference to
Circuit 11B further includes at least one pair of transistors coupled in a current mirror connection arrangement. More specifically, the gate of input side transistor ML(1) is coupled to the gate of output side transistor MC(1) and the commonly connected gate 32 is also connected to the drain of transistor ML(1). The source of transistor MC(1) is connected to voltage source VS through resistor R2 and the source of transistor ML(1) is connected to VS through resistor R3. The source of transistor MC(1) is also connected to the positive input of op amp 16 and provides a sensing voltage to op amp 16. The drain of transistor MC(1), designated as OUT(1), is coupled to a respective electrode (not shown) for delivery of stimulation current to the tissue in contact with such respective electrode.
The current mirror combination of transistors ML(1) and MC(1) is switchably coupled in a cascode arrangement to supply transistor MS through switch SA(1). More specifically, the drain of transistor ML(1) is coupled to one side of a “single pole single throw” switch SA(1) and the drain of transistor MS is coupled to the other side of switch SA(1). The source of transistor MS is coupled to voltage port 12, which for an anodic stimulator is ground and the gate of transistor MS is coupled to the output of op amp 16. For a cathodic stimulator, the voltage port is a voltage source such as VS. Switch SA(1) is controlled by logic circuits 35 such that when logic circuits 35 receive signal ANO from controller 30 and digital control signals DCS from digital registers 2, then logic circuits 35 actuate switch SA(1) (causes SA(1) to close) and stimulation current is delivered from output OUT(1) to its respective electrode. When logic circuits 35 de-activate switch SA(1) (causes SA(1) to open), current delivery from output OUT(1) is suspended.
Furthermore, at the same time, to ensure suspension of current delivery from output OUT(1), logic circuits 35 cause switch SB(1) to be activated. Stimulation therapy may be wirelessly controlled by an auxiliary device, such as a remote control or smart phone, to control the timing and duration of the activation of switches SA(1) and SB(1) so as to provide the desired current delivery in accordance with a predetermined therapy protocol. Preferably, logic circuits 35 control the states of switches SA(1) and SB(1) in a complementary fashion such that when switch SA(1) is activated, switch SB(1) is de-activated and vice versa.
Overall switching control can be accomplished by utilizing stimulation controller 30, digital registers 2 and logic circuits 35, either singly or in combination depending upon functional considerations.
Although the foregoing description relates to a single current mirror combination comprising transistors ML(1) and MC(1), multiple current mirror combinations are contemplated by the present invention. In this regard,
As is taught in the prior art for current mirror configurations, input side transistors will exactly mirror the current supplied to it by a current source to the output side transistor only when the transistors are accurately matched (See for example, U.S. Pat. No. 8,575,971). Accordingly, in such cases transistor fabrication requirements place an undue burden on manufacturing and processing techniques resulting in lower device yields and higher device costs. Advantageously, some applications of the present invention obviate the necessity of strict manufacturing processes for establishing transistor width and length dimensions for establishing desired circuit current gain values. As will be discussed below, some embodiments of the present invention rely on selected circuit resistor values to dependably establish required current gain values. More specifically, resistors R1 and R2 in combination with op amp 16 control the gate voltage of supply transistor MS for achieving an accurate overall stimulator output current IR2 flowing through resistor R2. As is to be noted in
As further shown in
Voltage VR1 is generated across resistor R1 when the current Isink flows from voltage source VS through resistor R1. In a like manner, voltage VR2 is generated across R2 when the overall stimulator output current IR2 flows through resistor R2 from voltage source VS. The voltage at the positive input of op amp 16 is the voltage sensed at the sources of transistors MC(1) to MC(n) when the corresponding switches SA(1) to SA(n) are activated and may be considered a common sensing voltage. Due to the feedback loop associated with op amp 16, the voltages at the positive and negative inputs of op amp 16 will be equal in steady state, and therefore, voltage VR2 is forced to be equal to VR1. At steady state, the current IR2 is equal to the sum of the output currents being delivered at all of the outputs OUT(1) to OUT(n). Accordingly, since VR2=IR2·R2 and VR1=Isink·R1, IR2 is equal to Isink·R1/R2 and the required overall current gain K defined as IR2/Isink, is therefore equal to R1/R2. Accordingly, setting the required overall current gain K is a matter of selecting the values of R1 and R2.
It is well known that resistors have better matched characteristics than MOSFETs in an integrated circuit for the same area. For the same part to part matching accuracy, using resistors in some applications of the present invention require less area on an integrated circuit than using MOSFETs. An additional benefit arising out of some applications of the present invention, relates to the manner in which the resistors R1 and R2 may be constructed. For example, resistor R2 may be made from a number (Np) of parallel resistors and R1 may be made from a number (Ns) of series resistors. Accordingly, for a resistor value R, R1=R·Ns and R2=R/Np and the current gain K=R1/R2=Ns·Np. For the case when Ns=Np=N, the current gain K=N2 and with the total number of resistors equal to 2N (Ns+Np=2N), the total number of required resistors as a function of current gain therefore is equal to 2·K1/2. For a required current gain of 100, the number of required resistors is 20, whereas a total of 101 individual transistors are required for M1 and M2 (See
In practice, transistors ML(1) and MC(1) are set to have a width (W) to length (L) or W/L ratio of 1:L and the ratio of R3 to R2 is set to L:1. As a result the current IR3 flowing through resistor R3 and hence the current ID4 flowing through transistor MS is approximately equal to the current flowing through resistor R2 (IR2) divided by L or equivalently ID4=Isink·K/L at steady state as the op amp 16 forces VR2 to equal VR1. In this case, the current ID4 is well defined and substantially independent of process and temperature variations.
A further novel advantage of the implementation of op amp 16 in the stimulator circuit 11B in some applications is that during circuit activation, that is, when stimulation controller 30 issues the ANO signal which causes Isink to flow to thereby provide VREF and with IR2 equal to zero amps, the voltage difference between VR1 and VR2 is large such that the output voltage of op amp 16 is very large. It is to be noted however, that logic circuits 35, timed whether it be just prior to or concurrent with the providing of VREF, activate at least one or more preselected switches SA(i) corresponding to the outputs OUT(i) through which current is selected to be delivered. As a consequence, op amp 16 drives supply transistor MS to have a large initial gate to source voltage to thereby produce a large initial drain current ID4. In turn, the gate voltages of the selected transistors MC(i) corresponding to the selected switches SA(i), are drawn down quickly for turning these transistors on quickly. In other words, a large initial current ID4 occurs to discharge the large gate capacitances of selected transistors MC(i) quickly, resulting in a very short stimulator turn on time. The large initial current ID4 is designed to discharge all of the gate capacitances of the selected transistors MC(i).
This novel advantage may be very important in some applications, especially for short output current pulses in some instances. As illustrated in
Waveform 54 in
Although it is possible to compensate for the shortening of the current pulses by adjusting the pulse width of ANO to be TD1 longer than the desired pulse width, the delay time TD1 is often dependent on the amplitudes (or levels) of Iout(i) and/or the total output current IR2 into all the stimulation electrodes. Furthermore, there will be variations in TD1 between different stimulators implemented in different ICs due to process variations. Therefore, it is very difficult to correctly compensate for the delay time TD1 by adjusting the pulse width of ANO. In some embodiments, it may be advantageous to have a pulse generator that is capable of short turn on time over a range of output currents. In one embodiment, for example, the pulse generator may have turn on times less than 10 us, 5 us, 2 us, 1 us or any other or intermediate value and/or between, approximately 0.1 and 2 us, 0.1 and 4 us, 0.1 and 10 us, 0.1 and 20 us, 0.2 and 16 us, 0.3 and 12 us, 0.4 and 8 us, 0.5 and 6 us, 0.5 and 4 us, 0.5 and 2 us, 0.5 and 1 us, or any other or intermediate turn on time. In some embodiments, these turn on times can be achieved for output currents of less than 100 mA, 75 mA, 50 mA, 25 mA, or any other or intermediate current, and/or between 50 uA and 100 mA, 100 uA and 75 mA, 150 uA and 50 mA, 200 uA and 25 mA, 500 uA and 10 mA, or any other or intermediate current. In some embodiments, and as used above, approximately can comprise 10 percent of the defined range.
For the embodiment shown in
Circuit 11A, 11B can be used in a variety of stimulation devices. In one embodiment, the above mentioned advantages of circuit 11A, 11B enable use of circuit 11A, 11B in a peripherally-implantable neurostimulation system for treating neuropathic pain or for other uses.
Approximately 8% of the Western (EU and US) population is affected by Neuropathic pain (chronic intractable pain due to nerve damage). In about 5% of people, this pain is severe. There are at least 200,000 patients that have chronic intractable pain involving a nerve. Neuropathic pain can be very difficult to treat with only half of patients achieving partial relief. Thus, determining the best treatment for individual patients remains challenging. Conventional treatments include certain antidepressants, anti-epileptic drugs and opioids. However, side effects from these drugs can be detrimental. In some of these cases, electrical stimulation, including FES, can provide effect treatment of this pain without the drug-related side effects.
A spinal cord stimulator, which is one type of FES device, is a device used to deliver pulsed electrical signals to the spinal cord to control chronic pain. Because electrical stimulation is a purely electrical treatment and does not cause side effects similar to those caused by drugs, an increasing number of physicians and patients favor the use of electrical stimulation over drugs as a treatment for pain. The exact mechanisms of pain relief by spinal cord stimulation (SCS) are unknown. The scientific background of the SCS trials was based initially on the Gate Control Theory of pain that was first described by Melzack and Wall in 1965. The theory posits that pain is transmitted by two kinds of afferent nerve fibers. One is the larger myelinated Aδ fiber, which carries quick, intense-pain messages. The other is the smaller, unmyelinated “C” fiber, which transmits throbbing, chronic pain messages. A third type of nerve fiber, called Aβ, is “non-nociceptive,” meaning it does not transmit pain stimuli. The gate control theory asserts that signals transmitted by the Aδ and C pain fibers can be thwarted by the activation/stimulation of the non-nociceptive Aβ fibers and thus inhibit an individual's perception of pain. Thus, neurostimulation provides pain relief by blocking the pain messages before they reach the brain.
At the present time, SCS is used mostly in the treatment of failed back surgery syndrome, a complex regional pain syndrome that has refractory pain due to ischemia. SCS complications have been reported in 30% to 40% of all SCS patients. This increases the overall costs of patient pain management and decreases the efficacy of SCS. Common complications include: infection, hemorrhaging, injury of nerve tissue, placing device into the wrong compartment, hardware malfunction, lead migration, lead breakage, lead disconnection, lead erosion, pain at the implant site, generator overheating, and charger overheating. The occurrence rates of common complications are surprisingly high: 9.5% are accounted for lead extension connection issues, 6% are due to lead breakage, 22.6% of cases are associated with lead migration and 4.5% experienced infection.
Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, viruses, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, diabetes, and vascular and metabolic disorders. Acquired peripheral neuropathies are grouped into three broad categories: those caused by systemic disease, those caused by trauma, and those caused by infections or autoimmune disorders affecting nerve tissue. One example of an acquired peripheral neuropathy is trigeminal neuralgia, in which damage to the trigeminal nerve (the large nerve of the head and face) causes episodic attacks of excruciating, lightning-like pain on one side of the face.
A high percentage of patients with peripheral neuropathic pain do not benefit from SCS for various reasons. However, many of these patients can receive acceptable levels of pain relief via direct electrical stimulation to the corresponding peripheral nerves. This therapy is called peripheral nerve stimulation (PNS). There is, however, no FDA approved PNS devices in the US market. Standard spinal cord stimulator (SCS) devices are often used off label by pain physicians to treat this condition. It is estimated that about 15% of SCS devices have been used off-label for PNS.
As current commercially-available SCS systems were designed for stimulating the spinal cord and not for peripheral nerve stimulation, there are more device complications associated with the use of SCS systems for PNS than for SCS. Current SCS devices (generators) are large and bulky. In the event that an SCS is used for PNS, the SCS generator is typically implanted in the abdominal or in the lower back above the buttocks and long leads are tunneled across multiple joints to reach the target peripheral nerves in the arms, legs or face. The excessive tunneling and the crossing of joints leads to increased post-surgical pain and higher device failure rates. Additionally, rigid leads can lead to skin erosion and penetration, with lead failure rates nearing 100% within 3 years of implantation. Most complications result in replacement surgery and even multiple replacement surgeries in some cases.
One embodiment of a peripherally-implantable neurostimulation system 600 is shown in
The peripherally-implantable neurostimulation system 600 can include one or several pulse generators. The pulse generators can comprise a variety of shapes and sizes, and can be made from a variety of materials. In some embodiments, the one or several pulse generators can generate electrical pulses that are delivered to the nerve to control pain. In some embodiments, a pulse generator can be an external pulse generator 602 or an implantable pulse generator 604. In some embodiments, an external pulse generator 602 can be used to evaluate the suitability of a patient for treatment with the peripherally-implantable neurostimulation system 600 and/or for implantation of an implantable pulse generator 604.
The implantable pulse generator 604 can be sized and shaped, and made of material so as to allow implantation of the implantable pulse generator 604 inside of a body. In some embodiments, the implantable pulse generator 604 can be sized and shaped so as to allow placement of the implantable pulse generator 604 at any desired location in a body, and in some embodiments, placed proximate to peripheral nerve such that leads (discussed below) are not tunneled across joints and/or such that extension cables are not needed. In some embodiments, the pulse generator, and specifically the implantable pulse generator 604 and/or the external pulse generator 602 can incorporate one of the circuits 11A, 11B, as shown in either or both of the embodiments of
In some embodiments, the electrical pulses generated by the pulse generator can be delivered to one or several nerves 610 and/or to tissue proximate to one or several nerves 610 via one or several leads. The leads can include conductive portions, referred to as electrodes, and non-conductive portions. The leads can have a variety of shapes, be a variety of sizes, and be made from a variety of materials, which size, shape, and materials can be dictated by the application or other factors.
In some embodiments, the leads can include an anodic lead 606 and/or a cathodic lead 608. In some embodiments, the anodic lead 606 and the cathodic lead 608 can be identical leads, but can receive pulses of different polarity from the pulse generator.
In some embodiments, the leads can connect directly to the pulse generator, and in some embodiments, the leads can be connected to the pulse generator via a connector 612 and a connector cable 614. The connector 612 can comprise any device that is able to electrically connect the leads to the connector cable 614. Likewise, the connector cable can be any device capable of transmitting distinct electrical pulses to the anodic lead 606 and the cathodic lead 608.
In some embodiments, the peripherally-implantable neurostimulation system 600 can include a charger 616 that can be configured to recharge the implantable pulse generator 604 when the implantable pulse generator 604 is implanted within a body. The charger 616 can comprise a variety of shapes, sizes, and features, and can be made from a variety of materials. In some embodiments, the charger 616 can recharge the implantable pulse generator 604 via an inductive coupling.
In some embodiments, details of the electrical pulses can be controlled via a controller. In some embodiments, these details can include, for example, the frequency, strength, pattern, duration, or other aspects of the timing and magnitude of the electrical pulses. This control of the electrical pulses can include the creation of one or several electrical pulse programs, plans, or patterns, and in some embodiments, this can include the selection of one or several pre-existing electrical pulse programs, plans, or patterns. In the embodiment depicted in
In some embodiments, the controller of the peripherally-implantable neurostimulation system 600 can include a patient remote 620. The patient remote 620 can comprise a computing device that can communicate with the pulse generators via a wired or wireless connection. The patient remote 620 can be used to program the pulse generator, and in some embodiments, the patient remote 620 can include one or several pulse generation programs, plans, or patterns created by the clinician programmer 618. In some embodiments, the patient remote 620 can be used to select one or several of the pre-existing pulse generation programs, plans, or patterns and to select, for example, the duration of the selected one of the one or several pulse generation programs, plans, or patterns.
Advantageously, the above outlined components of the peripherally-implantable neurostimulation system 600 can be used to control and provide the generation of electrical pulses to mitigate patient pain.
While the invention has been described by means of specific embodiments and applications thereof, it is understood that numerous modifications and variations could be made thereto by those skilled in the art without departing from the spirit and scope of the invention. It is therefore to be understood that within the scope of the claims, the invention may be practiced otherwise than as specifically described herein.
This application is a continuation of U.S. application Ser. No. 15/263,046 filed Sep. 12, 2016, entitled “CURRENT SENSING MULTIPLE OUTPUT CURRENT STIMULATORS,’ which is a divisional of U.S. application Ser. No. 14/217,321 filed Mar. 17, 2014, entitled “CURRENT SENSING MULTIPLE OUTPUT CURRENT STIMULATORS;” and issued as U.S. Pat. No. 9,446,241 on Sep. 20, 2016, which claims the benefit of U.S. Provisional Application No. 61/788,871 filed Mar. 15, 2013; the entirety of each which is hereby incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3646940 | Timm et al. | Mar 1972 | A |
3942535 | Schulman et al. | Mar 1976 | A |
4019518 | Maurer et al. | Apr 1977 | A |
4044774 | Corbin et al. | Aug 1977 | A |
4082097 | Mann et al. | Apr 1978 | A |
4340062 | Thompson et al. | Jul 1982 | A |
4468723 | Hughes | Aug 1984 | A |
4558702 | Barreras et al. | Dec 1985 | A |
4673867 | Davis | Jun 1987 | A |
4744371 | Harris | May 1988 | A |
5143089 | All | Sep 1992 | A |
5193539 | Schulman et al. | Mar 1993 | A |
5690693 | Wang et al. | Nov 1997 | A |
5702428 | Tippey et al. | Dec 1997 | A |
5702431 | Wang et al. | Dec 1997 | A |
5735887 | Barreras, Sr. et al. | Apr 1998 | A |
5741316 | Chen et al. | Apr 1998 | A |
5876423 | Braun | Mar 1999 | A |
5877472 | Campbell et al. | Mar 1999 | A |
6027456 | Feler et al. | Feb 2000 | A |
6035237 | Schulman et al. | Mar 2000 | A |
6055456 | Gerber | Apr 2000 | A |
6057513 | Ushikoshi et al. | May 2000 | A |
6067474 | Schulman et al. | May 2000 | A |
6076017 | Taylor et al. | Jun 2000 | A |
6164284 | Schulman et al. | Dec 2000 | A |
6172556 | Prentice | Jan 2001 | B1 |
6178353 | Griffith et al. | Jan 2001 | B1 |
6185452 | Schulman et al. | Feb 2001 | B1 |
6191365 | Avellanet | Feb 2001 | B1 |
6208894 | Schulman et al. | Mar 2001 | B1 |
6212431 | Hahn et al. | Apr 2001 | B1 |
6221513 | Lasater | Apr 2001 | B1 |
6246911 | Seligman | Jun 2001 | B1 |
6249703 | Stanton et al. | Jun 2001 | B1 |
6265789 | Honda et al. | Jul 2001 | B1 |
6306100 | Prass | Oct 2001 | B1 |
6313779 | Leung et al. | Nov 2001 | B1 |
6315721 | Schulman et al. | Nov 2001 | B2 |
6354991 | Gross et al. | Mar 2002 | B1 |
6360750 | Gerber et al. | Mar 2002 | B1 |
6393325 | Mann et al. | May 2002 | B1 |
6427086 | Fischell et al. | Jul 2002 | B1 |
6438423 | Rezai et al. | Aug 2002 | B1 |
6442434 | Zarinetchi et al. | Aug 2002 | B1 |
6466817 | Kaula et al. | Oct 2002 | B1 |
6505075 | Weiner | Jan 2003 | B1 |
6516227 | Meadows et al. | Feb 2003 | B1 |
6521350 | Fey et al. | Feb 2003 | B2 |
6564807 | Schulman et al. | May 2003 | B1 |
6584355 | Stessman | Jun 2003 | B2 |
6600954 | Cohen et al. | Jul 2003 | B2 |
6609031 | Law et al. | Aug 2003 | B1 |
6609032 | Woods et al. | Aug 2003 | B1 |
6652449 | Gross et al. | Nov 2003 | B1 |
6662051 | Eraker et al. | Dec 2003 | B1 |
6721603 | Zabara et al. | Apr 2004 | B2 |
6735474 | Loeb et al. | May 2004 | B1 |
6745077 | Griffith et al. | Jun 2004 | B1 |
6809701 | Amundson et al. | Oct 2004 | B2 |
6836684 | Rijkhoff et al. | Dec 2004 | B1 |
6847849 | Mama et al. | Jan 2005 | B2 |
6864755 | Moore | Mar 2005 | B2 |
6892098 | Ayal et al. | May 2005 | B2 |
6895280 | Meadows et al. | May 2005 | B2 |
6896651 | Gross et al. | May 2005 | B2 |
6901287 | Davis et al. | May 2005 | B2 |
6941171 | Mann et al. | Sep 2005 | B2 |
6971393 | Mama et al. | Dec 2005 | B1 |
6986453 | Jiang et al. | Jan 2006 | B2 |
6989200 | Byers et al. | Jan 2006 | B2 |
6990376 | Tanagho et al. | Jan 2006 | B2 |
6999819 | Swoyer et al. | Feb 2006 | B2 |
7051419 | Schrom et al. | May 2006 | B2 |
7054689 | Whitehurst et al. | May 2006 | B1 |
7069081 | Biggs et al. | Jun 2006 | B2 |
7114502 | Schulman et al. | Oct 2006 | B2 |
7127298 | He et al. | Oct 2006 | B1 |
7142925 | Bhadra et al. | Nov 2006 | B1 |
7146219 | Sieracki et al. | Dec 2006 | B2 |
7151914 | Brewer | Dec 2006 | B2 |
7167749 | Biggs et al. | Jan 2007 | B2 |
7177690 | Woods et al. | Feb 2007 | B2 |
7177698 | Klosterman et al. | Feb 2007 | B2 |
7181286 | Sieracki et al. | Feb 2007 | B2 |
7187978 | Malek et al. | Mar 2007 | B2 |
7191005 | Stessman | Mar 2007 | B2 |
7212110 | Martin et al. | May 2007 | B1 |
7225032 | Schmeling et al. | May 2007 | B2 |
7231254 | Dilorez | Jun 2007 | B2 |
7234853 | Givoletti | Jun 2007 | B2 |
7245972 | Davis | Jul 2007 | B2 |
7286880 | Olson et al. | Oct 2007 | B2 |
7305268 | Gliner et al. | Dec 2007 | B2 |
7317948 | King et al. | Jan 2008 | B1 |
7324852 | Barolat et al. | Jan 2008 | B2 |
7324853 | Ayal et al. | Jan 2008 | B2 |
7328068 | Spinelli et al. | Feb 2008 | B2 |
7330764 | Swoyer et al. | Feb 2008 | B2 |
7331499 | Jiang et al. | Feb 2008 | B2 |
7359751 | Erickson et al. | Apr 2008 | B1 |
7369894 | Gerber | May 2008 | B2 |
7386348 | North et al. | Jun 2008 | B2 |
7387603 | Gross et al. | Jun 2008 | B2 |
7396265 | Darley et al. | Jul 2008 | B2 |
7415308 | Gerber et al. | Aug 2008 | B2 |
7444181 | Shi et al. | Oct 2008 | B2 |
7450991 | Smith et al. | Nov 2008 | B2 |
7460911 | Cosendai et al. | Dec 2008 | B2 |
7463928 | Lee et al. | Dec 2008 | B2 |
7470236 | Kelleher et al. | Dec 2008 | B1 |
7483752 | Von Arx et al. | Jan 2009 | B2 |
7496404 | Meadows et al. | Feb 2009 | B2 |
7513257 | Schulman et al. | Apr 2009 | B2 |
7515967 | Phillips et al. | Apr 2009 | B2 |
7532936 | Erickson et al. | May 2009 | B2 |
7539538 | Parramon et al. | May 2009 | B2 |
7551960 | Forsberg et al. | Jun 2009 | B2 |
7555346 | Woods et al. | Jun 2009 | B1 |
7565203 | Greenberg et al. | Jul 2009 | B2 |
7578819 | Bleich et al. | Aug 2009 | B2 |
7580752 | Gerber et al. | Aug 2009 | B2 |
7582053 | Gross et al. | Sep 2009 | B2 |
7617002 | Goetz | Nov 2009 | B2 |
7636602 | Baru Fassio et al. | Dec 2009 | B2 |
7640059 | Forsberg et al. | Dec 2009 | B2 |
7643880 | Tanagho et al. | Jan 2010 | B2 |
7706889 | Gerber et al. | Apr 2010 | B2 |
7720547 | Denker et al. | May 2010 | B2 |
7725191 | Greenberg et al. | May 2010 | B2 |
7734355 | Cohen et al. | Jun 2010 | B2 |
7738963 | Hickman et al. | Jun 2010 | B2 |
7738965 | Phillips et al. | Jun 2010 | B2 |
7747330 | Nolan et al. | Jun 2010 | B2 |
7771838 | He et al. | Aug 2010 | B1 |
7774069 | Olson et al. | Aug 2010 | B2 |
7801619 | Gerber et al. | Sep 2010 | B2 |
7813803 | Heruth et al. | Oct 2010 | B2 |
7813809 | Strother et al. | Oct 2010 | B2 |
7826901 | Lee et al. | Nov 2010 | B2 |
7848818 | Barolat et al. | Dec 2010 | B2 |
7904167 | Klosterman et al. | Mar 2011 | B2 |
7912555 | Swoyer et al. | Mar 2011 | B2 |
7925357 | Phillips et al. | Apr 2011 | B2 |
7932696 | Peterson | Apr 2011 | B2 |
7933656 | Sieracki et al. | Apr 2011 | B2 |
7935051 | Miles et al. | May 2011 | B2 |
7937158 | Erickson et al. | May 2011 | B2 |
7952349 | Huang et al. | May 2011 | B2 |
7957818 | Swoyer | Jun 2011 | B2 |
7979119 | Kothandaraman et al. | Jul 2011 | B2 |
7979126 | Payne et al. | Jul 2011 | B2 |
7988507 | Darley et al. | Aug 2011 | B2 |
8000782 | Gharib et al. | Aug 2011 | B2 |
8000805 | Swoyer et al. | Aug 2011 | B2 |
8005535 | Gharib et al. | Aug 2011 | B2 |
8005549 | Boser et al. | Aug 2011 | B2 |
8005550 | Boser et al. | Aug 2011 | B2 |
8019423 | Passover | Sep 2011 | B2 |
8024047 | Olson et al. | Sep 2011 | B2 |
8036756 | Swoyer et al. | Oct 2011 | B2 |
8044635 | Peterson | Oct 2011 | B2 |
8050769 | Gharib et al. | Nov 2011 | B2 |
8055337 | Moffitt et al. | Nov 2011 | B2 |
8068912 | Kaula et al. | Nov 2011 | B2 |
8083663 | Gross et al. | Dec 2011 | B2 |
8103360 | Foster | Jan 2012 | B2 |
8116862 | Stevenson et al. | Feb 2012 | B2 |
8121701 | Woods et al. | Feb 2012 | B2 |
8129942 | Park et al. | Mar 2012 | B2 |
8131358 | Moffitt et al. | Mar 2012 | B2 |
8140168 | Olson et al. | Mar 2012 | B2 |
8145324 | Stevenson et al. | Mar 2012 | B1 |
8150530 | Wesselink | Apr 2012 | B2 |
8175717 | Hailer et al. | May 2012 | B2 |
8180451 | Hickman et al. | May 2012 | B2 |
8180452 | Shaquer | May 2012 | B2 |
8180461 | Mama et al. | May 2012 | B2 |
8214042 | Ozawa et al. | Jul 2012 | B2 |
8214048 | Whitehurst et al. | Jul 2012 | B1 |
8214051 | Sieracki et al. | Jul 2012 | B2 |
8219196 | Torgerson | Jul 2012 | B2 |
8219202 | Giftakis et al. | Jul 2012 | B2 |
8233990 | Goetz | Jul 2012 | B2 |
8255057 | Fang et al. | Aug 2012 | B2 |
8311636 | Gerber et al. | Nov 2012 | B2 |
8314594 | Scott et al. | Nov 2012 | B2 |
8332040 | Winstrom | Dec 2012 | B1 |
8340786 | Gross et al. | Dec 2012 | B2 |
8362742 | Kallmyer | Jan 2013 | B2 |
8369943 | Shuros et al. | Feb 2013 | B2 |
8386048 | McClure et al. | Feb 2013 | B2 |
8417346 | Giftakis et al. | Apr 2013 | B2 |
8423146 | Giftakis et al. | Apr 2013 | B2 |
8447402 | Jiang et al. | May 2013 | B1 |
8447408 | North et al. | May 2013 | B2 |
8457756 | Rahman | Jun 2013 | B2 |
8457758 | Olson et al. | Jun 2013 | B2 |
8480437 | Dilmaghanian et al. | Jul 2013 | B2 |
8494625 | Hargrove | Jul 2013 | B2 |
8515545 | Trier | Aug 2013 | B2 |
8538530 | Orinski | Sep 2013 | B1 |
8543223 | Sage et al. | Sep 2013 | B2 |
8549015 | Barolat | Oct 2013 | B2 |
8554322 | Olson et al. | Oct 2013 | B2 |
8555894 | Schulman et al. | Oct 2013 | B2 |
8562539 | Marino | Oct 2013 | B2 |
8571677 | Torgerson et al. | Oct 2013 | B2 |
8577474 | Rahman et al. | Nov 2013 | B2 |
8588917 | Whitehurst et al. | Nov 2013 | B2 |
8612002 | Faltys et al. | Dec 2013 | B2 |
8620436 | Parramon et al. | Dec 2013 | B2 |
8626314 | Swoyer et al. | Jan 2014 | B2 |
8644933 | Ozawa et al. | Feb 2014 | B2 |
8655451 | Klosterman et al. | Feb 2014 | B2 |
8700175 | Fell | Apr 2014 | B2 |
8725269 | Nolan et al. | May 2014 | B2 |
8738141 | Smith et al. | May 2014 | B2 |
8738148 | Olson et al. | May 2014 | B2 |
8750985 | Parramon et al. | Jun 2014 | B2 |
8761897 | Kaula et al. | Jun 2014 | B2 |
8768452 | Gerber | Jul 2014 | B2 |
8774912 | Gerber | Jul 2014 | B2 |
8954148 | Labbe et al. | Feb 2015 | B2 |
8989861 | Su et al. | Mar 2015 | B2 |
9089712 | Joshi et al. | Jul 2015 | B2 |
9108063 | Olson et al. | Aug 2015 | B2 |
20020116042 | Boling | Aug 2002 | A1 |
20030028072 | Fischell et al. | Feb 2003 | A1 |
20030078633 | Firlik et al. | Apr 2003 | A1 |
20040106963 | Tsukamoto et al. | Jun 2004 | A1 |
20050104577 | Matei et al. | May 2005 | A1 |
20050267546 | Parramon | Dec 2005 | A1 |
20060016452 | Goetz et al. | Jan 2006 | A1 |
20060050539 | Yang et al. | Mar 2006 | A1 |
20060142822 | Tulgar | Jun 2006 | A1 |
20060206166 | Weiner | Sep 2006 | A1 |
20070073357 | Rooney et al. | Mar 2007 | A1 |
20070265675 | Lund et al. | Nov 2007 | A1 |
20070293914 | Woods et al. | Dec 2007 | A1 |
20080132961 | Jaax et al. | Jun 2008 | A1 |
20080172109 | Rahman et al. | Jul 2008 | A1 |
20080183236 | Gerber | Jul 2008 | A1 |
20080278974 | Wu | Nov 2008 | A1 |
20090088816 | Harel et al. | Apr 2009 | A1 |
20090105785 | Wei et al. | Apr 2009 | A1 |
20090112291 | Wahlstrand et al. | Apr 2009 | A1 |
20090259273 | Figueiredo et al. | Oct 2009 | A1 |
20100076254 | Jimenez et al. | Mar 2010 | A1 |
20100076534 | Mock | Mar 2010 | A1 |
20110152959 | Sherwood et al. | Jun 2011 | A1 |
20110270269 | Swoyer et al. | Nov 2011 | A1 |
20110276103 | Maile et al. | Nov 2011 | A1 |
20110278948 | Forsell | Nov 2011 | A1 |
20110282416 | Hamann et al. | Nov 2011 | A1 |
20110301667 | Olson et al. | Dec 2011 | A1 |
20120016447 | Zhu et al. | Jan 2012 | A1 |
20120041512 | Weiner | Feb 2012 | A1 |
20120046712 | Woods et al. | Feb 2012 | A1 |
20120071950 | Archer | Mar 2012 | A1 |
20120119698 | Karalis et al. | May 2012 | A1 |
20120130448 | Woods et al. | May 2012 | A1 |
20120259381 | Smith et al. | Oct 2012 | A1 |
20120262108 | Olson et al. | Oct 2012 | A1 |
20120274270 | Dinsmoor et al. | Nov 2012 | A1 |
20120276854 | Joshi et al. | Nov 2012 | A1 |
20120276856 | Joshi et al. | Nov 2012 | A1 |
20130004925 | Labbe et al. | Jan 2013 | A1 |
20130006330 | Wilder et al. | Jan 2013 | A1 |
20130006331 | Weisgarber et al. | Jan 2013 | A1 |
20130023958 | Fell | Jan 2013 | A1 |
20130096651 | Ozawa | Apr 2013 | A1 |
20130148768 | Kim | Jun 2013 | A1 |
20130150925 | Vamos et al. | Jun 2013 | A1 |
20130197608 | Eiger | Aug 2013 | A1 |
20130207863 | Joshi | Aug 2013 | A1 |
20130211479 | Olson et al. | Aug 2013 | A1 |
20130303942 | Damaser et al. | Nov 2013 | A1 |
20130310894 | Trier | Nov 2013 | A1 |
20130331909 | Gerber | Dec 2013 | A1 |
20140222112 | Fell | Aug 2014 | A1 |
20140237806 | Smith et al. | Aug 2014 | A1 |
20140277268 | Lee | Sep 2014 | A1 |
20140277270 | Parramon et al. | Sep 2014 | A1 |
20150123608 | Dearden et al. | May 2015 | A1 |
20150214604 | Zhao et al. | Jul 2015 | A1 |
Number | Date | Country |
---|---|---|
1956750 | May 2007 | CN |
105164920 | Dec 2015 | CN |
102010006837 | Aug 2011 | DE |
1680182 | Jul 2006 | EP |
1904153 | Apr 2008 | EP |
2243509 | Oct 2010 | EP |
2003-047179 | Feb 2003 | JP |
2016512147 | Apr 2016 | JP |
2000-056677 | Mar 2000 | WO |
2000-066221 | Nov 2000 | WO |
2002003408 | Jan 2002 | WO |
2002-009808 | Feb 2002 | WO |
2004-103465 | Dec 2004 | WO |
2008021524 | Feb 2008 | WO |
2009-051539 | Apr 2009 | WO |
2009-091267 | Jul 2009 | WO |
2010-042056 | Apr 2010 | WO |
2010-042057 | Apr 2010 | WO |
2011059565 | May 2011 | WO |
2013141884 | Sep 2013 | WO |
2014146016 | Sep 2014 | WO |
2014146016 | Jan 2015 | WO |
Entry |
---|
Bosch, J., et al., Sacral (S3) Segmental Nerve Stimulation as a Treatment for Urge Incontinence in Patients With Detrusor Instability: Results of Chronic Electrical Stimulation Using an Implantable Neural Prosthesis, The Journal of Urology, Aug. 1995, vol. 154, pp. 504-507. |
Boiocchi, S., et al., “Self-calibration in high speed current steering CMOS D/A converters”, Advanced A-D and D-A Conversion Techniques and Their Applications, 1994, Second International Conference on Cambridge, UK, London, UK, IEE, UK, Jan. 1, 1994 (Jan. 1, 1994), pp. 148-152. |
Ghovanloo, M., et al., A Small Size Large Voltage Compliance Programmable Current Source for Biomedical Implantable Microstimulators, Proceedings of the 25th Annual International Conference of the IEEE EMBS, Sep. 17-21, 2003, pp. 1979-1982. |
Gundason, G., “A low-power ASK demodulator for Inductively coupled implantable electronics”, Solid-State Circuits Conference, 2000, Esscric ''00, Proceedings of the 26rd European, IEEE, Sep. 19, 2000, pp. 385-388. |
Humayun, M.S., et al., “A Variable Range Bi-Phasic Current Stimulus Driver Circuitry for an Implantable Retinal Prosthetic Device”, IEEE Journal of Solid-State Circuits, IEEE Service Center, Piscataw ay, NJ, USA, vol. 40, No. 3, Mar. 1, 2005, (Mar. 1, 2005), pp. 763-771. |
Sivaprakasam , “A Variable Range Bi-Phasic Current Stimulus Driver Circuitry for an Implantable Retinal Prosthetic Device”, IEEE Journal of Solid-State Circuits, IEEE Service Center, Piscataway, NJ, USA, vol. 40, No. 3 ISSN: 0018-9200, Mar. 1, 2005, pp. 763-771. |
Tanagho, E., et al., Bladder Pacemaker: Scientific Basis and Clinical Future, Urology, Dec. 1982, vol. 20, No. 6, pp. 614-619. |
Van Paemel, M., “High-Efficiency Transmission for Medical Implants”, IEEE Solid-State Circuits Magazine, IEEE, USA, vol. 3, No. 1, Jan. 1, 2011, pp. 47-59. |
Wang, Chua-Chin, et al., “A 140-dB CMRR Low-noise Instrumentation Amplifier for Neural Signal Sensing”, Circutis and Systems, 2006, APCCAS 2006, IEEE Asia Pacific Conference on IEEE, Piscataway, NJ, USA, Dec. 1, 2006 (Dec. 1, 2006), pp. 696-699. |
Number | Date | Country | |
---|---|---|---|
20190015664 A1 | Jan 2019 | US |
Number | Date | Country | |
---|---|---|---|
61788871 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14217321 | Mar 2014 | US |
Child | 15263046 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15263046 | Sep 2016 | US |
Child | 15980642 | US |